Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

Inclusion Criteria: For Normal Volunteers * Subject is ≥ 18 years old at the time of investigational product administration (Subject is male or female of any race / ethnicity) * Subject or subject's legally acceptable representative provides informed consent * Subject is capable of complying with study procedures * Subject is capable of communicating with study personnel For Cancer Subjects (same first four bullets as 'normals') * Subject must have had a diagnostic imaging study and is suspected of having a primary or metastatic tumor(s) ( \> 2 cm, except breast tumor)-sarcoma; melanoma; lung cancer \[including small cell and non-small cell lung cancer (NSCL)\]; high grade glioma (including glioblastoma multi-forms), anaplastic astrocytoma, and anaplastic oligodendroglioma; breast carcinomas, and head and neck tumors, including laryngeal squamous cell carcinoma * Subject is scheduled to have a clinical \[F-18\]FDG PET scan within ± 7 days (with no interventions between the two PET scans) of the investigational, \[F-18\]RGD-K5 PET scan * Subject is scheduled to undergo resection or biopsy of the target tumor as a result of routine clinical treatment * Subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET/CT imaging * Subject has laboratory test results within the following ranges: * AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limits of normal * Serum creatinine ≤ 1.5 institutional upper limits of normal…